On November 17, 2026, Sellas Life Sciences announced that its experimental blood cancer vaccine galinpepimut-S (GPS) reduced the risk of death by 41% in a Phase 3 trial for acute myeloid leukemia (AML) patients in remission unable to undergo stem-cell transplants. Patients treated with GPS achieved median overall survival of 24 months versus 14.7 months for best available treatment. Following the announcement, Sellas shares jumped over threefold, and the company plans to submit an FDA application in early 2027.
Phase 3 trial survival and efficacy results
- ▪Acute myeloid leukemia patients treated with galinpepimut-S achieved a median survival of 24 months, compared to 14.7 months for patients in the best available treatment control group
- ▪In a 126-patient Phase 3 clinical trial, Sellas Life Sciences' experimental cancer vaccine galinpepimut-S achieved its primary endpoint by significantly prolonging overall survival in acute myeloid leukemia patients
- ▪Galinpepimut-S reduced the risk of death by 41% compared to standard best available treatment in advanced acute myeloid leukemia patients
Mechanism of action and trial patient criteria
- ▪Galinpepimut-S trains the body's immune system to attack residual acute myeloid leukemia cells expressing the WT1 protein, exhibiting general patient tolerance without introducing new safety concerns
- ▪The Phase 3 trial evaluated galinpepimut-S specifically in acute myeloid leukemia patients who had achieved remission after initial therapy but were ineligible for bone marrow or stem-cell transplants
Sellas filing plans and executive commentary
- ▪New York-based Sellas Life Sciences plans to consult with the U.S. FDA regarding an accelerated filing strategy, aiming to submit an approval application in the first half of 2027
- ▪On November 17, 2026, Sellas Life Sciences Chief Executive Officer Angelos Stergiou stated on a conference call that delivering longer life without systemic toxicity would be transformative for fragile patients
Market reaction and analyst coverage
- ▪Following the trial results announcement on November 17, 2026, Sellas Life Sciences shares surged more than threefold to $22.93, adding approximately $3.1 billion to its market capitalization
- ▪Alliance Global Partners analyst James Molloy stated galinpepimut-S could secure expedited U.S. FDA approval as a monotherapy in 2027 and see off-label usage earlier in treatment paradigms
- ▪STAT News biotech columnist Adam Feuerstein acknowledged on November 17, 2026, that his September 2026 prediction forecasting galinpepimut-S would fail to prolong survival in Phase 3 testing was incorrect
Story comments
Loading comments…